2020 American Transplant Congress
Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression During the First Year Post-Transplant (<1yr Tx) Increases Risk for CMV Infection Through Inhibition of Anti-CMV Humoral Immunity
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have shown a higer CMV infection rate in kidney Tx patients (KTx Pts) who were converted to BLT 1yr post-Tx. Viral infections are…2020 American Transplant Congress
Belatacept Every Two Month Maintenance Dosing in Kidney Transplantation: A Randomized, Non-Inferiority Trial
Emory University School of Medicine, Atlanta, GA
*Purpose: Maintenance immunosuppression with belatacept following kidney transplantation results in a reduced risk of patient death and graft loss as compared to calcineurin inhibitors. However,…2020 American Transplant Congress
In Silico Deconvolution of Whole Blood RNA-Seq Data from Iscalimab Phase IIa Study in Renal Transplant Reveals Insights Into Mechanism of Action and Superiority of Iscalimab Compared to Tacrolimus
*Purpose: A recent Phase 2 clinical study indicated that iscalimab, a pathway blocking, non-depleting anti-CD40 antibody, showed non-inferiority on a composite clinical endpoint, and improved…2020 American Transplant Congress
Belatacept in Kidney Transplant Recipients with Previous Non-Renal Solid Organ Transplants
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: Selective co-stimulatory blockade with belatacept has demonstrated long-term benefits in renal transplantation, with improved glomerular filtration rate and decreased risk of death and graft…2020 American Transplant Congress
Dual and Opposite Costimulatory Targeting with a Novel Hybrid Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury in a Rat Bilateral Kidney Model
*Purpose: Many studies showed the CTLA4 effectiveness in the inhibition of CD28-CD80/86 costimulatory pathway in transplant and autoimmune diseases. Furthermore, the PD1-PDL1/2 interaction has been…2020 American Transplant Congress
Is it Time for Immune Screening for Belatacept-Treated Stable Kidney Transplant Patients for Adjust the Immunosuppression?
1ITAC, Buenos Aires, Argentina, 2CEFYBO, UBA, Buenos Aires, Argentina
*Purpose: Belatacept is a co-stimulation blocker for primary maintenance immunosuppression in kidney transplant recipients. The goal of this work was to study the immunological status…2020 American Transplant Congress
A Novel Injectable Hydrogel-Based Approach to Localize and Tune the Actuation of Enhanced Costimulation Blockade to the Strength of Transplant Rejection
*Purpose: Complications from long-term use of calcineurin inhibitors remain a major issue for transplant patients and alternative therapies are needed. The clinical efficacy of CTLA4-Ig…2020 American Transplant Congress
Analysis of Rejection, Rejection Therapy and Renal Function in the BEST Trial
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal) compared two belatacept (BELA)-based early corticosteroid withdrawal (ESW) regimens and alemtuzumab (ALEM) or rabbit antithymocyte globulin (rATG)…2020 American Transplant Congress
Effector Differentiation of Endogenous Antigen-Specific CD8+ T Cells is Selectively Limited by CTLA-4 Ig
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: Costimulation blockade with belatacept (CTLA-4 Ig) offers improved renal function and reduced toxicity following transplantation compared to calcineurin inhibitors. Nonetheless, episodes of acute T…2020 American Transplant Congress
Two Pilot Studies Exploring the Diagnostic and Predictive Potential of Serum LAG3 and FGL1 in Kidney Transplant Recipients
*Purpose: Lymphocyte activation gene 3 (LAG3), an immune checkpoint, plays an important role in the negative regulation of immune response and the induction of immune…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 30
- Next Page »